Geometrically Well‐Controlled Wireframe RNA Nanostructures With Bundled‐Helix Edges
Researchers have introduced a single‑stranded RNA origami platform that uses dual duplex bundles as wireframe edges, delivering markedly defined geometries. The approach enables the construction of intricate RNA polygons and grid lattices with high yield and structural fidelity. By bundling helices, the traditionally flexible RNA edges become rigid, reducing deformation. This advancement broadens the RNA nanostructure design toolkit and opens pathways for diverse bioengineering uses.
Kinase-Inactive RIPK3 Model Unveils Scaffold Role in Inflammation
Researchers created a kinase‑inactive RIPK3 D143N mouse that remains viable, revealing that RIPK3’s scaffold function alone can drive TNF‑induced inflammatory pathology. The mutant protein continues to recruit RIPK1, FADD and activate NF‑κB, producing cytokine storms without necroptotic cell death. In...
Assessing Targeted HIV and Harm Reduction Services
A new NIH‑backed assessment of targeted HIV prevention and harm‑reduction services in five major U.S. cities shows a 15% decline in new infections over the past year. The study attributes the drop to expanded syringe‑exchange programs, mobile testing units, and...
Cut Down on Oncology Drug Waste With Better Forecasting
Oncology drug waste reaches up to 30%, costing over $2 billion annually in the U.S. A 2023 CMS rule now forces manufacturers to refund Medicare for discarded volumes beyond a 10% threshold, adding financial pressure. Traditional forecasting relies on static sales...
Australia-Based Manufacturing to Deliver Custom mRNA Vaccines for Brain Cancer Trial
Southern RNA and Providence Therapeutics announced the PaedNEO‑VAX trial, a world‑first personalized mRNA vaccine study for children with advanced brain tumors. The multi‑site trial, funded by Providence, the Australian government and donors, will launch in March 2026 across eight pediatric...
Radiopharmaceutical Sector Shapes Supply Chain Around Fast-Decaying Products
Radiopharmaceutical manufacturers must design ultra‑fast supply chains because isotopes decay rapidly, turning each dose into a ticking clock. Companies such as NorthStar and Nucleus mitigate this by locating production near major airports, using private air freight for longer‑half‑life isotopes, and...
Drug-Controlled CAR T Cells May Enable Safer Immunotherapy
Researchers at EPFL have created a drug‑controlled CAR‑T platform called DROP‑CAR that can be turned off on demand with the FDA‑approved BCL‑2 inhibitor venetoclax. The system places a reversible protein‑protein interaction on the cell surface, causing the CAR to dissociate...
System Isolates Single Extracellular Vesicle Surface Proteins to Map Function
UC Davis engineers unveiled VESSEL, a cell‑free platform that produces extracellular vesicles bearing a single surface protein. By isolating individual proteins, the system enables direct functional mapping, exemplified by the discovery that CADM1 promotes vesicle uptake. The approach is scalable...
Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics announced rapid global regulatory clearance for MYCorzo, securing FDA, China NMPA, and European Commission approvals within a single week. The company launched the drug in the U.S. with over 700 REMS‑certified physicians and more than 12,000 customer engagements in...
Standard BioTools Inc (LAB) Q4 2025 Earnings Call Transcript
Pacific Biosciences reported Q4 2025 revenue of $44.6 million, a 14% year‑over‑year increase, driven by record consumable sales and higher Vega system placements. Consumables generated $21.6 million, up 15% YoY, pushing non‑GAAP gross margin to 40% for the quarter and the full...
Day One Biopharmaceuticals Inc (DAWN) Q4 2025 Earnings Call Transcript
Day One Biopharmaceuticals reported a breakout 2025, with Ojemda generating $155.4 million in net product revenue—a 172% year‑over‑year increase—and over 4,600 prescriptions. The company achieved its first profitability milestone as Ojemda’s revenue exceeded combined cost of sales and SG&A, while ending...
CareDx Inc (CDNA) Q4 2025 Earnings Call Transcript
CareDx reported Q4 2025 revenue of $108.4 million, up 25% year‑over‑year, propelled by testing services and a 47% surge in patient‑digital solutions. Adjusted EBITDA fell 34% because of a $6.7 million one‑time executive bonus, while cash balances reached $201 million and the company...
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Pharma reported Q4 2025 revenue of $120.7 million, a surge driven primarily by Attruby net product sales of $108.1 million and expanding royalty streams. The company announced statistically significant Phase III readouts for BBP-418 in limb‑girdle muscular dystrophy and...
Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences reported $714.7 million net product revenue for 2024, a 23% year‑over‑year increase, with Q4 sales of $201.3 million driven largely by its flagship narcolepsy drug Wakix. The company announced a generic settlement with Novogen that postpones competition until at least...
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Transcript
Incyte reported a strong Q4 2025, delivering $1.51 billion in revenue, a 28% year‑over‑year increase, and $5.14 billion for the full year, up 21%. Core products drove the surge: Jakafi posted $828 million in Q4 sales, Opsilura $207 million, and hematology/oncology sales jumped 121%...
Abcellera Biologics Inc (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Biologics reported a transformative 2024, shifting from a partnership platform to a clinical‑stage biotech. The company advanced two internal antibody programs, ABCL635 and ABCL575, toward CTA filings in Q2 2025 and highlighted a $800 million liquidity position. It outlined a...
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics reported third‑quarter product revenue of about $68 million, a 13% sequential increase, driven primarily by $58 million in Amtagvi sales and $10 million in Proleukin revenue. Gross margin improved to roughly 43% after a restructuring that cut cost of sales by...
Fulcrum Therapeutics Inc (FULC) Q4 2025 Earnings Call Transcript
Fulcrum Therapeutics reported a strong fourth‑quarter, posting $1.51 billion in revenue, a 28% year‑over‑year increase, and a full‑year 2025 revenue of $5.14 billion, up 21%. Core product sales accelerated, led by Jakafi’s $828 million Q4 revenue and Opsilura’s 28% sales jump to $207 million....
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Transcript
Vanda Pharmaceuticals reported a 9% rise in total revenue to $216.1 million for 2025, driven primarily by a 24% jump in Fanapt sales and a successful bipolar disorder launch. The company secured FDA approval for tradipitant (Nirius) for motion‑sickness prevention, marking...
Investors Overvalue Cagrisema Despite
Who are the people who thought cagrisema was worth this much for $NVO? I want to find and study them. The cross trial comparison data that we already had clearly showed Cagrisema was worse than $LLY by essentially the...
Animal Muscles Inspire Biomaterial Design for Agriculture, Fabrics and Medicine
Researchers at Washington University in St. Louis have engineered muscle‑inspired protein fibers using synthetic biology, creating filamin‑based threads that combine high tensile strength, toughness, damping and shape‑memory. By growing genetically modified microbes in bioreactors, they achieved higher protein yields and...
Denifanstat Posts Positive Phase III Results for Acne Treatment
Ascletis Pharma announced that its oral fatty‑acid‑synthase inhibitor denifanstat (ASC40) achieved positive Phase III results in moderate‑to‑severe acne vulgaris. In a 480‑patient double‑blind trial, 33% of participants reached clear or almost‑clear skin versus 15% on placebo, and an open‑label safety study...
Accelerating Next Generation Medicine with New Drug Delivery Platform
Scientists at the University of Nottingham have unveiled a modular materials platform that self‑assembles with RNA to form nanoscale delivery particles. The system uses reversible host‑guest linkages, allowing rapid tuning of stability and behavior for diverse therapeutic needs. In pre‑clinical...
Prime-Edited Therapy Restores Immune Function in Teen
Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency,...
Electrochemical Signals Can Reshape Bacterial Protein Patterns, Boosting Electron Transfer
Cornell researchers discovered that the inner‑membrane protein CymA in Shewanella oneidensis can self‑assemble into a biomolecular condensate, a behavior previously unseen in electroactive bacteria. By applying an external electrochemical signal, they induced the condensate, reorganizing CymA and its electron‑transfer partners...
Relationships Between an Aged Oral Microbiome and Harms Done by Senescent Cells
A new open‑access study investigates how the aging oral microbiome influences senescent cells and their SASP secretions, proposing a systemic oral‑microbiome‑senescence axis. The authors outline evidence that dysbiotic oral communities can exacerbate chronic inflammation and accelerate age‑related pathologies, yet they...
Gilead Deal Validates FDA One‑Trial Path, Boosts IMMX
$GILD $ACLX $7.8 billion acquisition 68% premium, Ph3 just starting. Validates new FDA policy for a single pivotal trial validated by BLA acceptance. Large pharma moving faster, de-risked. $IMMX thesis and data grows stronger, 95% (CR), same parallel strategy, and clear...
How a Sirtuin Protects Against Brain Diseases
Researchers in Aging Cell reveal that the nuclear sirtuin SIRT6 safeguards brain health by preserving nucleolar integrity and curbing excess protein synthesis. Loss of SIRT6 triggers nucleolar enlargement, heightened rRNA production, and uncontrolled protein translation, leading to protein aggregation and...
Merck Reorganizes Human Health Work Into Two New Units
Merck is reorganizing its Human Health division into two distinct units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen focus as its flagship immuno‑oncology drug Keytruda approaches patent expiry. Jannie Oosthuizen, formerly head of U.S. Human Health, will lead the Oncology...
The IPO Buzz: Generate Biomedicines (GENB Proposed) Launches $400 Million IPO
Generate Biomedicines, Inc. (GENB) launched a $400 million IPO on Feb 23, 2026, offering 25 million shares at $15‑$17 each on NASDAQ. At the midpoint price of $16, the company would be valued at roughly $2.04 billion. The proceeds are earmarked for two Phase 3 trials...
FDA Unveils Pathway for Ultra-Rare Disease Therapies
The FDA released draft guidance introducing the Plausible Mechanism Framework, a new approval pathway for individualized therapies targeting ultra‑rare diseases. The framework permits sponsors to seek clearance for gene‑editing and RNA‑based treatments when traditional randomized trials are infeasible due to...
Bringing Quantum Ideas to the Messy World of Disordered Proteins
Intrinsically disordered proteins (IDRs) make up roughly 79 % of human cancer‑associated proteins and defy traditional structure‑based drug design. Akshay Uttarkar’s team introduced QuPepFold, a Python package that translates short peptide sequences onto a tetrahedral lattice and uses a CVaR‑optimized...
Key Differences Between Anti‑cel and Cilta‑cel Explain GILD Deal
By chance I was writing about anito-cel vs. cilta-cel on Friday, not knowing $GILD acquisition was coming down the pike. There are some crucial differences between the two products to take note of, which may explain why they were...
What the FDA’s Priority Voucher Decision Means for Psychedelic Drug Development
The FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot compresses review timelines to one‑to‑two months for qualifying drugs, but its criteria favor applications with mature data packages. Compass Pathways’ synthetic psilocybin (COMP360) was listed as eligible yet did not receive...
How to Achieve Superior BCMA Response Rates without the Liability of Delayed MNTs
Recent analyses of BCMA CAR‑T therapies reveal that superior response rates can be achieved without the historically accepted trade‑off of delayed movement and neurocognitive toxicities (MNTs). Emerging data pinpoint specific construct features—particularly signaling domains and hinge designs—as the primary drivers...
Karma-Karma-Karma Chameleon
Balancing potency with oral bioavailability remains a core hurdle as drug candidates grow larger and more complex. Researchers now focus on "chameleonicity"—the ability of a molecule to toggle between polar and lipophilic conformations—to reconcile solubility and permeability. The article outlines...
Reading the Enemy: How Genome Science Is Reshaping the Fight Against Wheat Stem Rust
Researchers used long‑read DNA sequencing to assemble chromosome‑level genomes of two wheat stem‑rust strains that caused recent outbreaks in Ethiopia and Italy. The study showed these strains are unrelated to the notorious Ug99 lineage and each harbors distinct avirulence‑gene mutations...
Collaboration at Its Core: Launching Spain’s First Fully Integrated Spatial Omics Platform
IRB Barcelona has unveiled Spain’s first fully integrated spatial omics platform, uniting spatial transcriptomics, proteomics, histopathology, advanced microscopy and bioinformatics under one workflow. The facility draws on five core units to deliver an end‑to‑end pipeline from sample preparation through computational...
SGLT2s Linked to Lower Cardiorenal, Hepatic Risks in Type 2 Diabetes
A Taiwanese retrospective cohort of 24,259 adults with type 2 diabetes and liver cirrhosis found that initiating sodium‑glucose cotransporter‑2 inhibitors (SGLT2is) markedly reduced the risk of end‑stage kidney disease, acute kidney injury, major adverse cardiovascular events, all‑cause mortality, and hepatic decompensation...
BCAX's Phase 3 Ficera Dose Raises Critical Concerns
Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB
New Targeted Base-Editing Tool Corrects Genetic Brain Disorder in Mice
Researchers unveiled a TadA‑embedded adenine base editor (TeABE) that precisely corrects the pathogenic A‑T to G‑C mutation in the CHD3 gene of a mouse model of Snijders Blok‑Campeau syndrome. Delivered via a dual‑AAV viral system, the editor restored normal CHD3 protein...
FDA Approves New Biotronik Pacing Lead for LBBAP
Biotronik received FDA clearance for its Solia CSP S pacing lead, a device engineered specifically for left bundle branch area pacing (LBBAP). The lead combines a stylet‑driven platform with a novel fixed‑helix screw, addressing procedural simplicity and electrical performance. Approval relied on...
Silencing Ghrelin The Hunger Hormone
Recent research reveals that several snake lineages have completely lost the hunger hormone ghrelin and its activating enzyme, yet maintain normal energy balance. Modern anti‑obesity drugs, such as GLP‑1 receptor agonists, achieve weight loss by amplifying satiety signals rather than...
EU Pledges €225m to Develop Next Generation of Flu Vaccines
The European Commission has pledged €225 million through a pre‑commercial procurement model to accelerate the development of next‑generation influenza vaccines. Ten entities, including Sanofi and Bavarian Nordic, will receive eight‑year contracts that cover clinical testing through market authorisation. The funding targets...
Rival Drug Wins, Costs Us Marketing Gold
That feeling you get when you run a head-to-head study and the rival drug beats you out. Spending a fortune to hand your competitor a marketing message. Sometimes it feels like $NOVO is snake bit. $LLY https://t.co/gGUjl6iqPg
Detected Gene Count Isn’t a True Activity Metric
1/ Early scRNA‑seq papers sometimes treated “number of detected genes per cell” as a direct biological readout: more genes = more active cell, fewer genes = quiescent or distinct state. https://t.co/IjLWrR4uu7
Module 2, Section 1: Target Selection Strategy
The module outlines a five‑dimensional framework for target selection, linking biological relevance, drugability, disease impact, competitive landscape, and development risk. It contrasts first‑in‑class and best‑in‑class strategies, highlighting how pioneering mechanisms can command premium market positions. The content identifies oncology as...
Six RNAi Companies to Keep an Eye on in 2026
RNA interference (RNAi) has moved from a scientific curiosity to a fast‑growing therapeutic platform, with the global market projected to reach $1.97 billion by 2032. Six biotech firms—Aerska, ADARx, Alnylam, Arrowhead, City Therapeutics and SanegeneBio—are leading the next wave of innovation...
Bayesian Designs Decide Faster than Frequentist Group Sequential Methods
Goal-Driven Flexible Bayesian Design presentation updated w/comparison of performance of frequentist group sequential designs: https://t.co/QCZ6DQrm07 . Frequentist approach takes far too long to make a decision by controlling something that is NOT an error prob. #Statistics #rct https://t.co/X2knbmzTuX
Trump's Drug Pricing Deals Promise Lower Consumer Costs
My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs...